Bridgeway Capital Management’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Bridgeway Capital Management’s Portfolio CRXT Stock Details CRXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-45,000	Closed	-$17K	–	1476
2022 Q2	$17K	Sell	45,000 -45,000	-50%	-$31.5K	﹤0.01%	1313
2022 Q1	$134K	Buy	+90,000	New	+$114K	﹤0.01%	1232

Other funds holding CRXT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Bridgeway Capital Management's CRXT Position: Q3 2022 in Review

Bridgeway Capital Management sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 45,000 shares — an estimated $17K sold.

Bridgeway Capital Management first reported a position in CRXT in Q1 2022 and held it in 2 quarters. The position peaked at $134K in Q1 2022. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

Bridgeway Capital Management reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Bridgeway Capital Management sold 45,000 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $17K.
Bridgeway Capital Management first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
Bridgeway Capital Management's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $134K in Q1 2022.
2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Bridgeway Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.